{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:36:02Z","timestamp":1790516162619,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["ES16754"],"award-info":[{"award-number":["ES16754"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P50AG05136"],"award-info":[{"award-number":["P50AG05136"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.bcp.2013.12.014","type":"journal-article","created":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T21:45:11Z","timestamp":1389649511000},"page":"565-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Therapeutic implications of the prostaglandin pathway in Alzheimer's disease"],"prefix":"10.1016","volume":"88","author":[{"given":"Eiron","family":"Cudaback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas L.","family":"Jorstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Montine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Dirk","family":"Keene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2013.12.014_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(87)90696-3","article-title":"Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR","volume":"79","author":"McGeer","year":"1987","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2013.12.014_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0197-4580(88)80079-4","article-title":"Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease","volume":"9","author":"Rogers","year":"1988","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.014_bib0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0304-3940(88)90690-8","article-title":"Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue","volume":"91","author":"Itagaki","year":"1988","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2013.12.014_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02890024","article-title":"Complement activation in amyloid plaques in Alzheimer's dementia","volume":"56","author":"Eikelenboom","year":"1989","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1742-2094-9-179","article-title":"Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study","volume":"9","author":"Cribbs","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.bcp.2013.12.014_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0889-8561(02)00056-5","article-title":"Age-related inflammatory cytokines and disease","volume":"23","author":"Bruunsgaard","year":"2003","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.bcp.2013.12.014_bib0035","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/gerona\/glp046","article-title":"Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6","volume":"64","author":"Starr","year":"2009","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jnr.10192","article-title":"Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat","volume":"68","author":"Casolini","year":"2002","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.bcp.2013.12.014_bib0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040622311399145","article-title":"Cognitive dysfunction with aging and the role of inflammation","volume":"2","author":"Simen","year":"2011","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.bcp.2013.12.014_bib0050","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","article-title":"Systemic inflammation and disease progression in Alzheimer disease","volume":"73","author":"Holmes","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/archneurol.2009.308","article-title":"Association of C-reactive protein with cognitive impairment","volume":"67","author":"Noble","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0060","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrneurol.2012.156","article-title":"Gene expression profiling in human neurodegenerative disease","volume":"8","author":"Cooper-Knock","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0065","doi-asserted-by":"crossref","first-page":"a006346","DOI":"10.1101\/cshperspect.a006346","article-title":"Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature","volume":"2","author":"Wyss-Coray","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2013.12.014_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2013.05.009","article-title":"Proinflammatory cytokines, aging, and age-related diseases","author":"Michaud","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.bcp.2013.12.014_bib0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/187152710791012026","article-title":"Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence","volume":"9","author":"Szekely","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.bcp.2013.12.014_bib0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1749-6632.1988.tb27086.x","article-title":"Occurrence of HLA-DR reactive microglia in Alzheimer's disease","volume":"540","author":"McGeer","year":"1988","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0304-3940(89)90843-4","article-title":"Activation of the classical complement pathway in brain tissue of Alzheimer patients","volume":"107","author":"McGeer","year":"1989","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2013.12.014_bib0090","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0140-6736(90)91101-F","article-title":"Anti-inflammatory drugs and Alzheimer disease","volume":"335","author":"McGeer","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2013.12.014_bib0095","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/0140-6736(91)93122-P","article-title":"Rheumatoid arthritis and susceptibility to Alzheimer's disease","volume":"337","author":"Beard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2013.12.014_bib0100","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","article-title":"Clinical trial of indomethacin in Alzheimer's disease","volume":"43","author":"Rogers","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1212\/WNL.44.2.227","article-title":"Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study","volume":"44","author":"Breitner","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.45.1.51","article-title":"Nonsteroidal anti-inflammatory drugs in Alzheimer's disease","volume":"45","author":"Rich","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.48.3.626","article-title":"Risk of Alzheimer's disease and duration of NSAID use","volume":"48","author":"Stewart","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0120","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1212\/WNL.44.11.2073","article-title":"The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada","volume":"44","author":"Mcdowell","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4065\/73.10.951","article-title":"Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984","volume":"73","author":"Beard","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bcp.2013.12.014_bib0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.expneurol.2009.07.032","article-title":"Anti-inflammatory treatment in AD mice protects against neuronal pathology","volume":"223","author":"Choi","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0135","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1172\/JCI39716","article-title":"NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease","volume":"119","author":"Varvel","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2013.12.014_bib0140","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0002-9440(10)63269-5","article-title":"Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease","volume":"165","author":"Sung","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0145","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1523\/JNEUROSCI.20-15-05709.2000","article-title":"Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease","volume":"20","author":"Lim","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0150","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0197-4580(01)00299-8","article-title":"Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice","volume":"22","author":"Lim","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.014_bib0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.brainres.2008.01.095","article-title":"Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice","volume":"1207","author":"McKee","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.bcp.2013.12.014_bib0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.12059","article-title":"Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease","volume":"124","author":"Choi","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0165","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial","volume":"68","author":"Lyketsos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0170","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","article-title":"Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib","volume":"65","author":"Martin","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0175","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1371\/journal.pctr.0010041","article-title":"The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen","volume":"1","author":"Breitner","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.bcp.2013.12.014_bib0180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/gps.2723","article-title":"Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's disease anti-inflammatory prevention trial","volume":"27","author":"Leoutsakos","year":"2012","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.bcp.2013.12.014_bib0185","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jalz.2010.12.014","article-title":"Extended results of the Alzheimer's disease anti-inflammatory prevention trial","volume":"7","author":"Breitner","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.bcp.2013.12.014_bib0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tins.2010.05.004","article-title":"\u2018Too much good news\u2019\u2014are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?","volume":"33","author":"Zahs","year":"2010","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0195","doi-asserted-by":"crossref","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.bcp.2013.12.014_bib0200","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00332.2013","article-title":"A vasoconstrictor role for cyclooxygenase-1-mediated prostacyclin synthesis in mouse renal arteries","author":"Liu","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0205","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1021\/jm301905a","article-title":"Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors","volume":"56","author":"Vitale","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0210","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.contraception.2012.07.004","article-title":"Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women","volume":"87","author":"Edelman","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.bcp.2013.12.014_bib0215","first-page":"CD010648","article-title":"Titrated oral misoprostol for augmenting labour to improve maternal and neonatal outcomes","volume":"9","author":"Vogel","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bcp.2013.12.014_bib0220","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/carcin\/bgt020","article-title":"LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs","volume":"34","author":"Al-Kharusi","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2013.12.014_bib0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1475-2867-12-53","article-title":"Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo","volume":"12","author":"Dai","year":"2012","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bcp.2013.12.014_bib0230","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ana.23677","article-title":"Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease","volume":"72","author":"Shi","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.11.008","article-title":"Critical role of cPLA2 in Abeta oligomer-induced neurodegeneration and memory deficit","volume":"33","author":"Desbene","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.014_bib0240","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neuint.2013.09.007","article-title":"Cytosolic phospholipase Aalpha upregulation mediates apoptotic neuronal death induced by aggregated amyloid-beta peptide","volume":"63","author":"Sagy-Bross","year":"2013","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bcp.2013.12.014_bib0245","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1194\/jlr.M200298-JLR200","article-title":"Brain lipid metabolism in the cPLA2 knockout mouse","volume":"44","author":"Rosenberger","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bcp.2013.12.014_bib0250","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1098\/rstb.2011.0387","article-title":"The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling","volume":"367","author":"Reisenberg","year":"2012","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0255","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1209200","article-title":"Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation","volume":"334","author":"Nomura","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bcp.2013.12.014_bib0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.prostaglandins.2011.08.004","article-title":"Regulation of inflammation in cancer by eicosanoids","volume":"96","author":"Greene","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bcp.2013.12.014_bib0265","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1186034","article-title":"Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes","volume":"328","author":"Vegiopoulos","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bcp.2013.12.014_bib0270","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/378406a0","article-title":"Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II","volume":"378","author":"Dinchuk","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2013.12.014_bib0275","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0092-8674(00)80402-X","article-title":"Multiple female reproductive failures in cyclooxygenase 2-deficient mice","volume":"91","author":"Lim","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2013.12.014_bib0280","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2013.12.014_bib0285","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2013.12.014_bib0290","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/138161208784480171","article-title":"Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology","volume":"14","author":"Hoozemans","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bcp.2013.12.014_bib0295","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1006\/bbrc.1998.9981","article-title":"Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains","volume":"254","author":"Kitamura","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2013.12.014_bib0300","doi-asserted-by":"crossref","first-page":"13926","DOI":"10.1073\/pnas.162468699","article-title":"COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic\/antipyretic drugs: cloning, structure, and expression","volume":"99","author":"Chandrasekharan","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2013.12.014_bib0305","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1023\/B:NERE.0000035809.70905.8a","article-title":"Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells","volume":"29","author":"Cui","year":"2004","journal-title":"Neurochem Res"},{"key":"10.1016\/j.bcp.2013.12.014_bib0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jchemneu.2011.10.001","article-title":"Differential role of cyclooxygenase isozymes on neuronal density in hippocampus CA1 region of intracerebroventricular streptozotocin treated rat brain","volume":"43","author":"Dhull","year":"2012","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.bcp.2013.12.014_bib0315","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/gb-2004-5-9-241","article-title":"The cyclooxygenases","volume":"5","author":"Chandrasekharan","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0320","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainresbull.2007.02.015","article-title":"Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging","volume":"73","author":"Aid","year":"2007","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bcp.2013.12.014_bib0325","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.brainresbull.2006.03.006","article-title":"Regional protein levels of cytosolic phospholipase A2 and cyclooxygenase-2 in Rhesus monkey brain as a function of age","volume":"69","author":"Weerasinghe","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bcp.2013.12.014_bib0330","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1023\/B:NERE.0000023615.89699.63","article-title":"Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling","volume":"29","author":"Lukiw","year":"2004","journal-title":"Neurochem Res"},{"key":"10.1016\/j.bcp.2013.12.014_bib0335","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2013.12.014_bib0340","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1523\/JNEUROSCI.22-06-02246.2002","article-title":"Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice","volume":"22","author":"Jantzen","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0345","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.12059","article-title":"Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease","volume":"124","author":"Choi","year":"2012","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0350","article-title":"Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease","volume":"33","author":"Wilkinson","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.014_bib0355","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/aging.100021","article-title":"Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid","volume":"1","author":"Choi","year":"2009","journal-title":"Aging (Albany, NY)"},{"key":"10.1016\/j.bcp.2013.12.014_bib0360","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nbd.2010.01.019","article-title":"Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease","volume":"38","author":"Coma","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bcp.2013.12.014_bib0365","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nm1235","article-title":"Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production","volume":"11","author":"Kukar","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2013.12.014_bib0370","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/00005072-199911000-00003","article-title":"Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons","volume":"58","author":"Yermakova","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0375","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s004010000251","article-title":"Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain","volume":"101","author":"Hoozemans","year":"2001","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0380","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI18162","article-title":"NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2013.12.014_bib0385","doi-asserted-by":"crossref","first-page":"31831","DOI":"10.1074\/jbc.M303592200","article-title":"Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity","volume":"278","author":"Weggen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0390","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1074\/jbc.M111.305227","article-title":"First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms","volume":"287","author":"Borgegard","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0395","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2013.12.014_bib0400","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nature07055","article-title":"Substrate-targeting gamma-secretase modulators","volume":"453","author":"Kukar","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2013.12.014_bib0405","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2013.12.014_bib0410","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0415","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/01.wnl.0000313933.17796.f6","article-title":"No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies","volume":"70","author":"Szekely","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0420","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1074\/jbc.273.12.6689","article-title":"Mechanism of prostaglandin E2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter \u201cPGT\u201d","volume":"273","author":"Chan","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0425","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.7754369","article-title":"Identification and characterization of a prostaglandin transporter","volume":"268","author":"Kanai","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bcp.2013.12.014_bib0430","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1172\/JCI118897","article-title":"Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT)","volume":"98","author":"Lu","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2013.12.014_bib0435","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neuro.2011.02.004","article-title":"Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity","volume":"32","author":"Milatovic","year":"2011","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0440","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.4155\/fmc.11.136","article-title":"Identification and development of mPGES-1 inhibitors: where we are at?","volume":"3","author":"Chang","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0445","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbalip.2009.01.021","article-title":"EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1\/2 activation","volume":"1791","author":"Israel","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2013.12.014_bib0450","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.neurobiolaging.2011.09.017","article-title":"PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease","volume":"33","author":"Zhen","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.014_bib0455","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2353\/ajpath.2010.090840","article-title":"Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow","volume":"177","author":"Keene","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0460","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1523\/JNEUROSCI.3591-05.2005","article-title":"Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease","volume":"25","author":"Liang","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0465","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1471-4159.2011.07567.x","article-title":"Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP(4) receptor","volume":"120","author":"Hoshino","year":"2012","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0470","doi-asserted-by":"crossref","first-page":"18493","DOI":"10.1074\/jbc.M109.003269","article-title":"Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor","volume":"284","author":"Hoshino","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.12.014_bib0475","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2353\/ajpath.2009.081153","article-title":"Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2","volume":"174","author":"Keene","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0480","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/jcbfm.2013.69","article-title":"Prostaglandin E2 type 1 receptors contribute to neuronal apoptosis after transient forebrain ischemia","volume":"33","author":"Shimamura","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bcp.2013.12.014_bib0485","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/jcbfm.2008.88","article-title":"The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic","volume":"29","author":"Abe","year":"2009","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bcp.2013.12.014_bib0490","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11481-012-9380-1","article-title":"Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid beta neurotoxicity in vitro","volume":"8","author":"Li","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0495","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1037\/0022-006X.54.2.231","article-title":"Multimodal assessment of impulsiveness in abusing, neglecting, and nonmaltreating mothers and their preschool children","volume":"54","author":"Rohrbeck","year":"1986","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0500","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yexmp.2013.01.002","article-title":"Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease","volume":"94","author":"Cimino","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0505","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.expneurol.2009.01.016","article-title":"Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor","volume":"217","author":"Savonenko","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0510","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.4049\/jimmunol.0903487","article-title":"The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity","volume":"184","author":"Shi","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0515","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2004.03.013","article-title":"Prostaglandin E2 regulates amyloid precursor protein expression via the EP2 receptor in cultured rat microglia","volume":"362","author":"Pooler","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2013.12.014_bib0520","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2006.12.012","article-title":"Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury","volume":"184","author":"Ahmad","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0525","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ijc.28076","article-title":"Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer","volume":"133","author":"O\u2019Callaghan","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bcp.2013.12.014_bib0530","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2220\/biomedres.27.49","article-title":"Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats","volume":"27","author":"Ikeda","year":"2006","journal-title":"Biomed Res"},{"key":"10.1016\/j.bcp.2013.12.014_bib0535","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bjp.0704958","article-title":"Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestine","volume":"137","author":"Shahbazian","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0540","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1476-5381.2012.02088.x","article-title":"Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor","volume":"168","author":"Birrell","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0545","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1165\/rcmb.2012-0158OC","article-title":"Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes","volume":"48","author":"Aso","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0550","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thx.2010.158568","article-title":"EP4 receptor as a new target for bronchodilator therapy","volume":"66","author":"Buckley","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.bcp.2013.12.014_bib0555","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1476-5381.2009.00275.x","article-title":"Dual modulation of urinary bladder activity and urine flow by prostanoid EP3 receptors in the conscious rat","volume":"158","author":"Jugus","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0560","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jneuroim.2011.06.014","article-title":"Inhibition of prostaglandin E2 EP3 receptors improves stroke injury via anti-inflammatory and anti-apoptotic mechanisms","volume":"238","author":"Ikeda-Matsuo","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0565","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.plefa.2006.04.002","article-title":"Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery","volume":"74","author":"Hung","year":"2006","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.bcp.2013.12.014_bib0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2012.01.041","article-title":"Prostaglandin E(2) induced contraction of human intercostal arteries is mediated by the EP(3) receptor","volume":"681","author":"Longrois","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0575","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.jnen.0000240472.43038.27","article-title":"Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease","volume":"66","author":"Mohri","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.bcp.2013.12.014_bib0580","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.neurobiolaging.2005.12.011","article-title":"Determinants of platelet activation in Alzheimer's disease","volume":"28","author":"Ciabattoni","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.014_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.07.014","article-title":"Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight","volume":"33","author":"Amtul","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.014_bib0590","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0197-0186(92)90147-J","article-title":"Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease","volume":"21","author":"Wong","year":"1992","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bcp.2013.12.014_bib0595","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1073\/pnas.0701585104","article-title":"Lipocalin-type prostaglandin D synthase\/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid","volume":"104","author":"Kanekiyo","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2013.12.014_bib0600","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1212\/01.wnl.0000312383.39973.88","article-title":"An aberrant protein complex in CSF as a biomarker of Alzheimer disease","volume":"70","author":"Lovell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0605","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neuropharm.2005.09.008","article-title":"Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells","volume":"50","author":"Bate","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0610","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainresbull.2004.04.016","article-title":"Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer's disease","volume":"64","author":"Kim","year":"2004","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bcp.2013.12.014_bib0615","series-title":"Oxidative stress and age-related neurodegeneration","author":"Yuan","year":"2006"},{"key":"10.1016\/j.bcp.2013.12.014_bib0620","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/cn3000795","article-title":"Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease","volume":"3","author":"Soper","year":"2012","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0625","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1523\/JNEUROSCI.0684-08.2008","article-title":"Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice","volume":"28","author":"Shineman","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2013.12.014_bib0630","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096588","article-title":"Long-term efficacy and safety of celecoxib in Alzheimer's disease","volume":"23","author":"Soininen","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.bcp.2013.12.014_bib0635","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03325217","article-title":"A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease","volume":"21","author":"Pasqualetti","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.bcp.2013.12.014_bib0640","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0645","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0650","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2013.12.014_bib0655","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2013.12.014_bib0660","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/WAD.0b013e3181611024","article-title":"A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study","volume":"22","author":"Gomez-Isla","year":"2008","journal-title":"Alzheimer Dis Assoc Disord"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213007983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213007983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T02:18:39Z","timestamp":1716430719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295213007983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0006295213007983"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2013.12.014","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic implications of the prostaglandin pathway in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2013.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}